|1.||Buck, Elizabeth: 4 articles (02/2012 - 09/2009)|
|2.||Zhang, Yan: 2 articles (03/2015 - 05/2012)|
|3.||Poondru, Srinivasu: 2 articles (02/2015 - 02/2015)|
|4.||Gedrich, Rich: 2 articles (02/2015 - 02/2015)|
|5.||Simantov, Ronit: 2 articles (02/2015 - 02/2015)|
|6.||Flanigan, Sara A: 2 articles (11/2013 - 11/2010)|
|7.||Tentler, John J: 2 articles (11/2013 - 11/2010)|
|8.||Leong, Stephen: 2 articles (11/2013 - 11/2010)|
|9.||Tan, Aik Choon: 2 articles (11/2013 - 11/2010)|
|10.||Eckhardt, S Gail: 2 articles (11/2013 - 11/2010)|
02/15/2015 - "The purpose of this study was to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary activity of OSI-906 in patients with advanced solid tumors. "
02/15/2015 - "These results support further evaluation of OSI-906 in solid tumors."
02/15/2015 - "These data support further evaluation of OSI-906 in solid tumors."
01/01/2014 - "TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. "
05/01/2012 - "When given once a week, simultaneous administration of OSI-906 and DOX significantly enhanced the anti-tumor effect of DOX. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
03/01/2015 - "This study aimed to understand the effects of programmed cell death 4 (Pdcd4) on the chemosensitivity of the IGF-1R inhibitor OSI-906 in colorectal cancer cells and the mechanism underlying this impact. "
11/15/2013 - "Results from this study demonstrate synergistic antiproliferative effects in response to the combination of OSI-906 with an MEK 1/2 inhibitor in colorectal cancer cell line models both in vitro and in vivo, which supports the rational combination of OSI-906 with an MEK inhibitor in patients with colorectal cancer. "
03/01/2015 - "Knockdown of p70S6K1, but not p70S6K2, significantly increases the chemosensitivity of OSI-906 in cultured colorectal cancer cells. "
03/01/2015 - "Using OSI-906-resistant and -sensitive colorectal cancer cells, we found that the Pdcd4 level directly correlates with cell chemosensitivity to OSI-906. "
11/15/2013 - "In addition, the efficacy of OSI-906 combined with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) was evaluated in vivo using human colorectal cancer xenograft models. "
06/01/2014 - "OSI-906 at a dose equivalent to the clinical daily dose (7.5 mg/kg) transiently evoked glucose intolerance and hyperinsulinemia. "
06/01/2014 - "Insulin receptor substrate (IRS)-2-deficient mice and mice with diet-induced obesity, both models of peripheral insulin resistance, exhibited more severe glucose intolerance after OSI-906 administration than glucokinase-haploinsufficient mice, a model of impaired insulin secretion. "
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Somatomedin Receptors (Somatomedin Receptor)
|5.||Mitogen-Activated Protein Kinase Kinases (MEKs)
|6.||IGF Type 1 Receptor (IGF 1 Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)